The development of a commercial route toward the JAK1 inhibitor abrocitinib is described. The application of a late-stage Lossen rearrangement provided the desired cis-diaminocyclobutane, which was subsequently sulfonylated using a novel water-tolerable triazole sulfonylating reagent to provide the active pharmaceutical ingredient.

中文翻译：

---

用于JAK1抑制剂阿布罗替尼商业路线的丁二烯型重排的开发。

描述了朝着JAK1抑制剂阿布罗替尼的商业途径的发展。后期Lossen重排的应用提供了所需的顺式-二氨基环丁烷，随后使用新型的耐水三唑磺酰化试剂将其磺酰化，以提供活性药物成分。